Core Insights - Liu Yiqian and his family have recently pledged shares in Changjiang Securities and Hendi Pharmaceutical, totaling nearly 5 billion yuan, indicating a contraction in their business empire [1][3] - Liu Yiqian's wealth has accumulated to 39 billion yuan, ranking 675th on the Hurun Global Rich List, but his business empire is visibly shrinking due to significant losses in subsidiaries [3] Summary by Sections Changjiang Securities - Changjiang Securities announced that its major shareholder, New Liyi Group, will conduct a stock pledge repurchase transaction, involving 2.9 million shares from Minqiong Limited and 1.22 million shares from Zhuang Bin Limited, totaling 7.44% of the company's equity [1] - The pledged shares are valued at approximately 3.746 billion yuan based on the closing price of 9.1 yuan per share on November 10 [1] Hendi Pharmaceutical - Liu Yiqian's family members pledged a total of 72.5 million shares in Hendi Pharmaceutical, representing 17.36% of the company's total equity, for "investment cooperation" purposes [2] - The pledged shares are valued at around 1.151 billion yuan based on the closing price of 15.88 yuan per share [2] Liu Yiqian's Background - Liu Yiqian, known as the "King of Corporate Shares," began his career as a taxi driver in the mid-1980s and became a prominent figure in the financial market in the 1990s [2] - He founded New Liyi Group in 2000 and has been involved in numerous financing projects, earning the nickname "Magic Master of Financing" [2] Financial Performance and Challenges - Liu Yiqian's core platform, Tianmao Group, faced delisting risks and was eventually delisted, leading to a personal wealth decline of over 10 billion yuan [3] - Changjiang Securities reported its highest revenue and net profit since its listing, but New Liyi Group's influence has diminished as it has become the second-largest shareholder [3] - Liu Yiqian's stake in Yuncong Technology has been reduced to 1.58%, and he has exited the top ten shareholders of several companies [3]

Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]

Healthcare Policy - National Healthcare Security Administration held a series of discussions on the adjustment of the disease-based payment grouping scheme 3.0, involving over 70 representatives from medical institutions and industry associations [1] Drug and Medical Device Approvals - Shijiazhuang Pharmaceutical Group's application for the listing of Pertuzumab injection has been accepted by the National Medical Products Administration, targeting HER2-positive breast cancer [1] - Huason Pharmaceutical received a registration certificate for its special medical purpose formula food, Ganyimei®, designed for patients over 10 years old with strict fat restrictions and digestive absorption disorders [2] - United Imaging Healthcare's subsidiary obtained a medical device registration certificate for its color Doppler ultrasound diagnostic system, enhancing its product range across various market segments [3] - Yiling Pharmaceutical's application for the listing of Memantine Hydrochloride, a drug for treating moderate to severe Alzheimer's disease, has been approved [4] - Zhifei Biological's clinical trial application for a freeze-dried varicella inactivated vaccine has been accepted by the National Medical Products Administration [10] - Changchun High-tech's subsidiary received approval for a clinical trial of an acellular pertussis-diphtheria-tetanus combined vaccine for adolescents and adults [11] Capital Market Activities - Peking University Pharmaceutical announced the release of 34,615,386 shares from pledge, representing 51.52% of the pledged shares and 5.81% of the total share capital [5] - Kelun Pharmaceutical received approval for a registration of 4 billion yuan in ultra-short-term financing bonds, with a validity period of 2 years [6][7] - Baili Tianheng decided to delay its global offering and listing of H-shares due to current market conditions [8] - Aipeng Medical announced a plan for a shareholder to reduce holdings by up to 1% of total shares, citing personal funding needs [12] - Hendi Pharmaceutical's shareholders plan to collectively reduce their holdings by up to 2.33% of total shares for personal financial planning [13] Financial Adjustments - Baihua Pharmaceutical plans to use 1.91 billion yuan from its capital reserve to cover losses, primarily due to goodwill impairment from a previous major asset restructuring [14]

Core Viewpoint - Hendi Pharmaceutical (301211.SZ) experienced a midday decline of 5.35%, closing at 14.67 yuan, with a total market capitalization of 6.126 billion yuan due to shareholder reduction plans [1] Shareholder Reduction Plans - Three shareholders of Hendi Pharmaceutical plan to collectively reduce their holdings by no more than 2.33% of the company's shares [1] - Shareholder Ningkang Qichuan intends to reduce holdings by up to 4.176 million shares (1% of total share capital) [1] - Shareholder Beikang Qichuan plans to reduce holdings by up to 1.392 million shares (0.33% of total share capital) [1] - Shareholder Lei Xiaoyan also plans to reduce holdings by up to 4.176 million shares (1% of total share capital) [1] - The reduction will be executed through block trading or centralized bidding, with the reason cited as personal financial planning by the shareholders [1]

Core Viewpoint - Hendi Pharmaceutical (301211) announced that three shareholders plan to collectively reduce their holdings by up to 2.33% of the company's shares due to personal financial planning [1][2]. Shareholder Reduction Details - Shareholder Ningkang Enterprise Management Center (Limited Partnership) holds 23,490,000 shares (5.63% of total shares) and plans to reduce up to 4,176,000 shares (1%) within three months after the announcement [1]. - Shareholder Beikang Enterprise Management Center (Limited Partnership) holds 7,830,000 shares (1.88% of total shares) and plans to reduce up to 1,392,000 shares (0.33%) within three months after the announcement [1]. - Shareholder Lei Xiaoyan holds 15,660,000 shares (3.75% of total shares) and plans to reduce up to 4,176,000 shares (1%) within three months after the announcement [1]. Market Performance - Hendi Pharmaceutical's stock price approached its yearly high, reaching 16.95 yuan per share on November 10, close to the year's peak of 16.97 yuan [2]. - On November 12, the stock price fell by 2.39%, closing at 15.50 yuan per share, with a total market capitalization of 6.473 billion yuan [2]. Financial Performance - The three shareholders' total potential cash-out from the share reduction could be up to 151 million yuan based on the latest stock price [3]. - For the first three quarters, the company reported revenue of 319 million yuan, a year-on-year decrease of 4.52%, and a net profit attributable to shareholders of 20.93 million yuan, down 71.96% [3]. - The third quarter alone saw revenue of 84.13 million yuan, a decline of 8.68%, and a net profit of 2.39 million yuan, down 61.3% [3]. - The company has experienced continuous negative growth in revenue and net profit since the first quarter of the previous year, primarily due to a decrease in the sales volume of ibuprofen [3].

Core Points - On November 12, Century Huatong announced a share repurchase plan of 500 million to 1 billion yuan for capital reduction [1][2] - A total of 18 A-share listed companies disclosed share reduction plans, indicating a trend of shareholder divestment [1][2] Summary of Share Repurchase - Century Huatong plans to repurchase shares worth between 500 million and 1 billion yuan to reduce registered capital [2] Summary of Share Reductions - Tai Xiang Co. plans to reduce no more than 1% of its shares by shareholder Zhongyuan Investment [2] - Jiang Bolong's second-largest shareholder has completed a reduction of 4.1915 million shares [2] - Senior management of Zhejiang Zhongcheng plans to reduce their holdings [2] - Controlling shareholder of Hexing Packaging intends to reduce no more than 1.91% of shares [2] - Shareholder Wang Ge of Dongfang Zhongke plans to reduce no more than 0.51% of shares [2] - Executive Yu Qingchi of Kuai Publishing plans to reduce no more than 0.02% of shares [2] - Directors and executives of Changlian Co. plan to collectively reduce no more than 0.77% of shares [2] - China Unicom's structural adjustment fund reduced 40.7003 million shares from November 10 to November 12 [2] - Shareholder Chen Bei of Ruimaite plans to reduce no more than 1.76% of shares [2] - Shareholder Zhang Hong of Aipeng Medical plans to reduce no more than 2% of shares [2] - Director Wo Jinye of Jujiao Co. plans to reduce no more than 0.01% of shares [2] - Directors and executives of Zhonglan Environmental Protection plan to reduce their holdings [2] - Shareholders Ning Kangqi and Beikangqi of Hendi Pharmaceutical plan to collectively reduce no more than 2.33% of shares [2] - Wuxi High-tech Zone New Momentum Industry Development Fund reduced 549,200 shares of Xiangnan Chip [2] - Controlling shareholder of Tianji Co. sold 8.4 million shares during a period of significant stock trading volatility [2] - The second-largest shareholder of Fangzheng Electric reduced a total of 1.6324 million shares on November 10 and 12 [2] - Controlling shareholder of Haodangjia plans to reduce no more than 2.7% of shares [2] - Controlling shareholder of Zhibang Home reduced 905,000 convertible bonds [2]

Group 1 - The core point of the article is that Hendi Pharmaceutical reported a total of 22,155 shareholders as of November 10, 2025 [2]

Summary of Key Points Core Viewpoint - The article discusses various companies and their shareholders' intentions to buy or sell shares, indicating a trend of both increasing and decreasing shareholdings among different firms in the market [1]. Company Actions - 康缘药业's actual controller's concerted action party increased holdings by 80,000 shares [1]. - 好当家's controlling shareholder plans to reduce holdings by no more than 2.7% [1]. - 亨迪药业's shareholders, including 宁康企管, 倍康企管, and 雷小艳, intend to collectively reduce holdings by no more than 2.33% [1]. - 合兴包装's controlling shareholder 新疆兴汇聚 plans to reduce holdings by no more than 1.91% [1]. - 瑞迈特's shareholder 陈蓓 intends to reduce holdings by no more than 1.76% [1]. - 泰祥股份's 众远投资 plans to reduce holdings by no more than 1% [1]. - 香农芯创's 无锡高新区新动能产业发展基金 reduced holdings by 549,200 shares [1]. - 中国联通's structural adjustment fund will reduce holdings by 40,700,300 shares from November 10 to November 12 [1]. - 方正电机's shareholder 张敏 reduced holdings by 1,632,400 shares [1]. - 畅联股份's directors 徐峰 and 陈文晔 plan to reduce holdings by 0.57% and 0.20%, respectively [1]. - 中兰环保's shareholders 王广庆, 曹丽, and 李泉 plan to reduce holdings by 0.0375%, 0.2798%, and 0.0275%, respectively [1]. - 聚胶股份's director 沃金业 plans to reduce holdings by 0.01% [1]. - 浙江众成's executives 黄旭生 and 潘德祥 plan to reduce holdings by 0.0140% [1]. - 东方中科's shareholder 王戈 plans to reduce holdings by 0.51% [1]. - 海南瑞泽's vice president 于清池 plans to reduce holdings by no more than 0.02% [1].

公告显示，宁康企管本次计划合计减持数量不超过417.6万股，不超过公司总股本的1%；倍康企管本次 计划合计减持数量不超过139.2万股，不超过公司总股本的0.33%；雷小艳本次计划合计减持数量不超过 417.6万股，不超过公司总股本的1%。 北京商报讯（记者 丁宁）11月12日晚间，亨迪药业（301211）发布公告称，公司于近日收到宁康企 管、倍康企管、雷小艳出具的《关于股份减持计划的告知函》。 ...

Core Viewpoint - Hendi Pharmaceutical (301211.SZ) announced plans for significant share reductions by major shareholders, indicating potential changes in ownership structure and market sentiment towards the company [1] Group 1: Shareholder Reductions - Jingmen Ningkang Enterprise Management Center (Limited Partnership), holding 23,490,000 shares (5.63% of total shares), plans to reduce its holdings by up to 4,176,000 shares (1% of total shares) within three months after the announcement [1] - Jingmen Beikang Enterprise Management Center (Limited Partnership), holding 7,830,000 shares (1.88% of total shares), intends to reduce its holdings by up to 1,392,000 shares (0.33% of total shares) within three months after the announcement [1] - Lei Xiaoyan, holding 15,660,000 shares (3.75% of total shares), plans to reduce her holdings by up to 4,176,000 shares (1% of total shares) within three months after three trading days from the announcement [1]